Janus Henderson Group PLC Inozyme Pharma, Inc. Transaction History

Janus Henderson Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.57 - $5.45 $576,654 - $1.22 Million	-224,379 Reduced 24.13%	705,577 $1.91 Million
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.96 $1.31 Million - $2.44 Million	409,193 Added 78.58%	929,956 $4.46 Million
Q1 2022 May 16, 2022	BUY	$3.87 - $7.55 $1.53 Million - $2.99 Million	395,610 Added 316.1%	520,763 $2.12 Million
Q4 2021 Feb 14, 2022	BUY	$5.58 - $11.5 $698,353 - $1.44 Million	125,153 New	125,153 $857,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.